Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 868 matching trials from the live ClinicalTrials.gov search.
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Conditions
Lung Diseases, Cancer
Interventions
Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Idiopathic Hypersomnia
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 14 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Obinutuzumab, CC-486
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Prostate Cancer
Interventions
ZD4054 (Zibotentan), Docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee
Conditions
Ovarian Cancer
Interventions
THEO-260
Biological
Lead sponsor
Theolytics Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cystitis, Interstitial
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
122
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Conditions
Castration-resistant Prostate Cancer
Interventions
BEZ235, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Hackensack, New Jersey
Conditions
Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis
Interventions
INS1202
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 4 more
Conditions
Acute Myeloid Leukemia
Interventions
Erwinase
Drug
Lead sponsor
Ashkan Emadi
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
ADVM-043
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Charleston, South Carolina
Conditions
Lupus Nephritis
Interventions
BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Conditions
Neoplasms
Interventions
BI 765179, Ezabenlimab, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more
Conditions
Osteoarthritis of the Knee
Interventions
Bone morphogenetic protein 7, Placebo
Drug
Lead sponsor
Stryker Biotech
Industry
Eligibility
40 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Glendale, Arizona • Tucson, Arizona • Palo Alto, California + 20 more
Conditions
Male Erectile Disorder, Prostate Cancer, Radiation Toxicity
Interventions
Placebo, Oral L-Arginine
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions
IMG-007, Placebo
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
sodium phenylbutyrate, tretinoin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Interventions
Momelotinib (MMB), Trametinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • Boston, Massachusetts + 2 more
Conditions
Endometriosis
Interventions
Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD - Treatment B, Leuprolide Oral Tablet - 60 mg - QD - Treatment C, Leuprolide Oral Tablet - 60 mg - BID - Treatment D, Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Drug
Lead sponsor
Enteris BioPharma Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more
Conditions
Mast Cell Activation Syndrome
Interventions
Masitinib 4.5 mg/kg/day, Placebo, Best supportive care, Masitinib 6.0 mg/kg/day
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Weldon Spring, Missouri